These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 17538545)
41. Anthropometric definitions for antiretroviral-associated lipodystrophy derived from a longitudinal South African cohort with serial dual-energy X-ray absorptiometry measurements. Abrahams Z; Maartens G; Levitt N; Dave J Int J STD AIDS; 2018 Oct; 29(12):1194-1203. PubMed ID: 29945538 [TBL] [Abstract][Full Text] [Related]
42. Antiretroviral-therapy-associated lipoatrophy: current status and future directions. Nolan D; Mallal S Sex Health; 2005; 2(3):153-63. PubMed ID: 16335543 [TBL] [Abstract][Full Text] [Related]
43. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Cossarizza A; Riva A; Pinti M; Ammannato S; Fedeli P; Mussini C; Esposito R; Galli M Antivir Ther; 2003 Aug; 8(4):315-21. PubMed ID: 14518701 [TBL] [Abstract][Full Text] [Related]
44. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report. Parruti G; Toro GM BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141 [TBL] [Abstract][Full Text] [Related]
45. Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition. Casula M; van der Valk M; Wit FW; Nievaard MA; Reiss P HIV Med; 2007 Jan; 8(1):32-7. PubMed ID: 17305930 [TBL] [Abstract][Full Text] [Related]
46. The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. Martinez E; Visnegarwala F; Grund B; Thomas A; Gibert C; Shlay J; Drummond F; Pearce D; Edwards S; Reiss P; El-Sadr W; Carr A; AIDS; 2010 Jan; 24(3):353-63. PubMed ID: 20057309 [TBL] [Abstract][Full Text] [Related]
47. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Gerschenson M; Shiramizu B; LiButti DE; Shikuma CM Antivir Ther; 2005; 10 Suppl 2():M83-9. PubMed ID: 16152709 [TBL] [Abstract][Full Text] [Related]
49. Disorders of fat partitioning in treated HIV-infection. Martínez E Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):415-27. PubMed ID: 21663836 [TBL] [Abstract][Full Text] [Related]
50. Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy. Bickel M; Zangos S; Lutz T; Eisen J; Knecht G; Goebel FD; Crespi CM; Jacobi V; Staszewski S; Klauke S Scand J Infect Dis; 2008; 40(1):36-9. PubMed ID: 17852925 [TBL] [Abstract][Full Text] [Related]
51. Case files from the Bellevue Hospital Center at New York University--lipoatrophy following long-term antiretroviral therapy. Daskalakis D; Aberg JA MedGenMed; 2005 Oct; 7(4):9. PubMed ID: 16614631 [No Abstract] [Full Text] [Related]
52. No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. Ortiz M; Poloni ES; Furrer H; Kovari H; Martinez R; Arnedo M; Elzi L; Bernasconi E; Vernazza P; Hirschel B; Cavassini M; Ledergerber B; Günthard HF; Telenti A; Tarr PE; J Infect Dis; 2011 Mar; 203(5):620-4. PubMed ID: 21227914 [TBL] [Abstract][Full Text] [Related]
54. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz. Viganò A; Brambilla P; Cafarelli L; Giacomet V; Borgonovo S; Zamproni I; Zuccotti G; Mora S Antivir Ther; 2007; 12(3):297-302. PubMed ID: 17591019 [TBL] [Abstract][Full Text] [Related]
55. Peripheral blood mitochondrial DNA/nuclear DNA (mtDNA/nDNA) ratio as a marker of mitochondrial toxicities of stavudine containing antiretroviral therapy in HIV-infected Malawian patients. Kampira E; Dzobo K; Kumwenda J; van Oosterhout JJ; Parker MI; Dandara C OMICS; 2014 Jul; 18(7):438-45. PubMed ID: 24816082 [TBL] [Abstract][Full Text] [Related]
56. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study. Ribera E; Larrousse M; Curran A; Negredo E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Ferrer P; Alvarez ML; Arterburn S; Martínez E HIV Med; 2013 Jul; 14(6):327-36. PubMed ID: 23298339 [TBL] [Abstract][Full Text] [Related]
57. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study. Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852 [TBL] [Abstract][Full Text] [Related]
58. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Nolan D; Hammond E; James I; McKinnon E; Mallal S Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896 [TBL] [Abstract][Full Text] [Related]
59. Pathogenesis and management of lipoatrophy. Tungsiripat M; McComsey G Curr HIV/AIDS Rep; 2008 May; 5(2):55-63. PubMed ID: 18510890 [TBL] [Abstract][Full Text] [Related]
60. Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome. Domingo P; Torres-Torronteras J; Pomar V; Giralt M; Domingo JC; Gutierrez Mdel M; Gallego-Escuredo JM; Mateo MG; Cano-Soldado P; Fernandez I; Pastor-Anglada M; Vidal F; Villarroya F; Andreu A; Marti R PLoS One; 2010 Nov; 5(11):e13896. PubMed ID: 21085568 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]